R
Remo H.M. Furtado
Researcher at University of São Paulo
Publications - 68
Citations - 5110
Remo H.M. Furtado is an academic researcher from University of São Paulo. The author has contributed to research in topics: Medicine & Myocardial infarction. The author has an hindex of 14, co-authored 49 publications receiving 3121 citations. Previous affiliations of Remo H.M. Furtado include Brigham and Women's Hospital & Albert Einstein Hospital.
Papers
More filters
Journal ArticleDOI
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker,Stephen D. Wiviott,Itamar Raz,KyungAh Im,Erica L. Goodrich,Marc P. Bonaca,Ofri Mosenzon,Eri Toda Kato,Avivit Cahn,Remo H.M. Furtado,Deepak L. Bhatt,Lawrence A. Leiter,Darren K. McGuire,John P.H. Wilding,Marc S. Sabatine +14 more
TL;DR: SGLT2i have moderate benefits on atherosclerotic major adverse cardiovascular events that seem confined to patients with established atheroscerotic cardiovascular disease, however, they have robust benefits on reducing hospitalisation for heart failure and progression of renal disease regardless of existing atherosclerosis or a history of heart failure.
Journal ArticleDOI
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.
Alexandre Biasi Cavalcanti,Fernando G. Zampieri,Regis Goulart Rosa,Luciano Cesar Pontes Azevedo,Viviane C Veiga,Alvaro Avezum,Lucas P. Damiani,Aline Marcadenti,Leticia Kawano-Dourado,Thiago Lisboa,Debora L. M. Junqueira,Pedro Gabriel Melo de Barros e Silva,Lucas Tramujas,Erlon Oliveira de Abreu-Silva,Lígia Nasi Laranjeira,Aline T. Soares,Leandro S. Echenique,Adriano José Pereira,Flávio Geraldo Resende Freitas,Otavio Gebara,Vicente C.S. Dantas,Remo H.M. Furtado,Eveline P. Milan,Nicole A. Golin,Fábio F. Cardoso,Israel Silva Maia,Conrado R. Hoffmann Filho,Adrian P.M. Kormann,Roberto Bleuel Amazonas,Monalisa Fernanda Bocchi de Oliveira,Ary Serpa-Neto,Maicon Falavigna,Renato D. Lopes,Flávia Ribeiro Machado,Otavio Berwanger +34 more
TL;DR: Among patients hospitalized with mild-to-moderate Covid-19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with standard care.
Journal ArticleDOI
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Thomas A Zelniker,Stephen D. Wiviott,Itamar Raz,KyungAh Im,Erica L. Goodrich,Remo H.M. Furtado,Marc P. Bonaca,Ofri Mosenzon,Eri Toda Kato,Avivit Cahn,Deepak L. Bhatt,Lawrence A. Leiter,Darren K. McGuire,John P.H. Wilding,Marc S. Sabatine +14 more
TL;DR: GLP1-RA and SGLT2i reduce atherosclerotic MACE to a similar degree in patients with established atherosclerosis cardiovascular disease, whereas SGLG2i has a more marked effect on preventing hospitalization for heart failure and progression of kidney disease.
Journal ArticleDOI
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Eri Toda Kato,Michael G. Silverman,Ofri Mosenzon,Thomas A Zelniker,Avivit Cahn,Remo H.M. Furtado,Julia F Kuder,Sabina A. Murphy,Deepak L. Bhatt,Lawrence A. Leiter,Darren K. McGuire,John P.H. Wilding,Marc P. Bonaca,Christian T. Ruff,Akshay S. Desai,Shinya Goto,Peter A. Johansson,Ingrid Gause-Nilsson,Per Johanson,Anna Maria Langkilde,Itamar Raz,Marc S. Sabatine,Stephen D. Wiviott +22 more
TL;DR: In the first sodium-glucose cotransporter 2 inhibitor cardiovascular outcome trial to evaluate patients with type 2 diabetes mellitus stratified by EF, it is found that dapagliflozin reduced HHF in patients with and without HFrEF and reduced cardiovascular death and all-cause mortality in Patients with HFr EF.
Journal ArticleDOI
Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial.
Renato D. Lopes,Pedro Gabriel Melo de Barros e Silva,Remo H.M. Furtado,Ariane Vieira Scarlatelli Macedo,Bruna Bronhara,Lucas P. Damiani,Lilian Mazza Barbosa,Júlia de Aveiro Morata,Eduardo Ramacciotti,Priscilla de Aquino Martins,Aryadne Lyrio de Oliveira,Vinicius Santana Nunes,Luiz Eduardo Fonteles Ritt,Ana Thereza Rocha,Lucas Tramujas,Sueli V Santos,Dario Rafael Abregu Diaz,Lorena Souza Viana,Livia Maria Garcia Melro,Mariana Silveira de Alcântara Chaud,Estêvão Lanna Figueiredo,Fernando Carvalho Neuenschwander,Marianna Deway Andrade Dracoulakis,Rodolfo Godinho Souza Dourado Lima,Vicente C.S. Dantas,Anne Cristine Silva Fernandes,Otavio Gebara,Mauro E. Hernandes,Diego Aparecido Rios Queiroz,Viviane C Veiga,Manoel Fernandes Canesin,Leonardo Meira de Faria,Gilson Soares Feitosa-Filho,Marcelo Basso Gazzana,Idelzuíta Leandro Liporace,Aline de Oliveira Twardowsky,Lilia Nigro Maia,Flávia Ribeiro Machado,Alexandre de Matos Soeiro,Germano Emílio Conceição-Souza,Luciana Armaganijan,Patrícia O. Guimarães,Regis Goulart Rosa,Luciano Cesar Pontes Azevedo,John H. Alexander,Alvaro Avezum,Alexandre Biasi Cavalcanti,Otavio Berwanger +47 more
TL;DR: In this paper, the authors compared the efficacy and safety of therapeutic versus prophylactic anticoagulation in patients hospitalised with COVID-19 in 31 sites in Brazil, and found that in the case of stable patients, in-hospital oral rivaroxaban (20 mg or 15 mg daily) or initial subcutaneous enoxaparin (1 mg/kg twice per day) or intravenous unfractionated heparin (to achieve a 0·3-0·7 IU/mL anti-Xa concentration) for clinically unstable patients, followed